LNK INTL INC
GenericsLNK INTL INC is a generic drug manufacturer focused on Immunology.
LNK INTL INC's Key Drugs
LNK INTL INC's core commercial portfolio centers on ACETAMINOPHEN AND IBUPROFEN, spanning Immunology — its most strategically important drugs approved in the last 15 years.
LNK INTL INC's Recent FDA Approvals
New NDA/BLA approvals for LNK INTL INC over the last two years — novel drugs only, excluding generics and label supplements.
LNK INTL INC's Therapeutic Areas
LNK INTL INC's approved drugs and pipeline span 1 therapeutic area, led by Immunology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
LNK INTL INC's Top Competitors
LNK INTL INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
LNK INTL INC Pipeline Snapshot
Active clinical trials for LNK INTL INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ACETAMINOPHEN AND IBUPROFEN leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2017-01-23
- Latest
- 2025-12-11
- Applications
- 2